Rohail Saleem • May 11, 2025

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
Persistent hair loss is a non-life-threatening yet debilitating condition that adversely affects self-confidence, potentially constituting a major trigger for anxiety and depression.
It is hardly a surprise, therefore, that the market size of hair loss treatment products, including shampoos, conditioners, and serums, in the US alone is currently estimated at $2.22 billion. Critically, this estimation does not include pharmaceutical interventions such as Minoxidil-based products, hair transplant procedures, or other niche treatments such as Platelet-Rich Plasma (PRP).
Now, however, there is a new cause for optimism among the millions of people around the world that continue to suffer as a result of age-related or premature hair loss.
https://twitter.com/MarioNawfal/status/1921593642210484623 (archive)

To wit, a UCLA research team has now developed the molecule PP405, which when applied topically, can re-activate dormant hair follicles without any major side effects (as per the results of early trials).
The research team has also founded Pelage Pharmaceuticals, a medical development company that is backed by Google Ventures, to market the drug.
In fact, PP405 can stimulate the growth of thick, terminal hair in as little as a week, and that too without the fertility-related issues presented by alternative treatments such as Minoxidil. Moreover, the drug showed no systemic body absorption or detectable levels in blood samples, as per the results of clinical trials to date.
On the granular level, PP405 is able to activate stem cells that would otherwise lie dormant within hair follicles. These stem cells then go on to produce new, terminal hair.
Of course, you will have to wait a little while longer to get your hands on PP405, which is currently undergoing phase 2 trials in the US. If everything checks out, PP405-based hair loss treatments are expected to hit the market between 2027 and 2030.